GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » EV-to-Revenue

I-MAB (IMAB) EV-to-Revenue : -40.07 (As of May. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, I-MAB's enterprise value is $-154.83 Mil. I-MAB's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $3.86 Mil. Therefore, I-MAB's EV-to-Revenue for today is -40.07.

The historical rank and industry rank for I-MAB's EV-to-Revenue or its related term are showing as below:

IMAB' s EV-to-Revenue Range Over the Past 10 Years
Min: -44.69   Med: 12.84   Max: 527.23
Current: -40.07

During the past 7 years, the highest EV-to-Revenue of I-MAB was 527.23. The lowest was -44.69. And the median was 12.84.

IMAB's EV-to-Revenue is ranked better than
98.65% of 1037 companies
in the Biotechnology industry
Industry Median: 7.95 vs IMAB: -40.07

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-14), I-MAB's stock price is $1.85. I-MAB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.05. Therefore, I-MAB's PS Ratio for today is 40.22.


I-MAB EV-to-Revenue Historical Data

The historical data trend for I-MAB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB EV-to-Revenue Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial - 11.23 226.76 4.31 -38.19

I-MAB Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 226.76 - 4.31 - -38.19

Competitive Comparison of I-MAB's EV-to-Revenue

For the Biotechnology subindustry, I-MAB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


I-MAB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where I-MAB's EV-to-Revenue falls into.



I-MAB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

I-MAB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-154.830/3.864
=-40.07

I-MAB's current Enterprise Value is $-154.83 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. I-MAB's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $3.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


I-MAB  (NAS:IMAB) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

I-MAB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.85/0.046
=40.22

I-MAB's share price for today is $1.85.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was $0.05.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


I-MAB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of I-MAB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


I-MAB (IMAB) Business Description

Traded in Other Exchanges
Address
555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.